#USA #Cleveland #Seed Funding #Coologics #Vlisse

Coologics Inc. Raises Over $3 Million in Seed Funding

Coologics Inc., a pioneering company focused on women's health, has successfully closed an oversubscribed seed funding round, securing more than $3 million to develop its innovative product, Vlisse. The successful funding round exceeded the company's initial target of $1.5 million, demonstrating significant investor confidence in the need for new solutions in treating vaginal infections.

Strong Investor Interest

Led by Prevail and Dream Ventures, this funding round attracted substantial interest from various investors, including alumni networks from the Ohio State University and the University of Illinois. Dr. Kim Langdon, the CEO and founder of Coologics, shares their excitement regarding the overwhelming support received from investors. "The commitment of our investors signals a pressing demand for effective treatments targeting vaginal infections, a concern that affects many women worldwide."

Innovative Solution for Vaginal Infections

The funds will primarily be allocated towards completing ongoing clinical trials, preparing for FDA submissions, and launching Vlisse into the market. This innovative product is designed as a drug-free, intravaginal cooling device that aims to alleviate conditions such as Vulvovaginal Candidiasis (VVC) and Bacterial Vaginosis (BV) without reliance on traditional antifungal medications. By leveraging its patented cooling mechanism, Vlisse seeks to restore the vaginal environment to a healthy state, contributing to a paradigm shift in treating these common infections.

"Dr. Langdon's vision for addressing this health issue was a key factor that attracted us to Coologics," stated Kerry Lawing, CEO of Prevail Ventures. "The market is in dire need of innovative solutions like Vlisse, and we look forward to supporting Coologics in bringing this product to fruition."

Addressing a Critical Need

This funding round marks a significant moment in Coologics' journey towards enhancing women’s health by delivering sustainable treatments that minimize the overuse of antibiotics—a rising concern in today’s medical landscape. With the successful closure of the seed funding, Coologics is now poised to accelerate its development efforts and deliver effective solutions to women seeking relief from vaginal infections.

Dr. Langdon emphasizes the importance of this endeavor, stating, "Our mission lies in acknowledging and addressing the subtle but profound health issues that women face in their everyday lives. The completion of this funding reflects our commitment to innovate and provide effective, drug-free options for care."

Looking Ahead

As Coologics embarks on this new phase, the company remains committed to supporting women's health through research-driven innovation. The anticipated market entry of Vlisse is set to offer a fresh and impactful alternative for women struggling with vaginal infections, ensuring they have access to safe and effective health solutions.

Coologics Inc. is dedicated to reshaping women's healthcare by utilizing the latest in medical technology to create solutions that are not only effective but also mindful of the growing concern surrounding antibiotic resistance. For more details about their groundbreaking product and ongoing efforts, visit Coologics' official website.

For media inquiries, contact Rich Mazzola, CFO at Coologics, at 216-376-7972.